Topic:

M&A

Latest Headlines

Latest Headlines

Becton Dickinson plans respiratory asset sale in wake of CareFusion merger

Becton Dickinson is reviewing its assets now that the $12.4 billion CareFusion deal closed last week. The $30 billion medical products and diagnostics company is expected to sell the respiratory device business that was formerly part of CareFusion, Bloomberg reports.

AbbVie's $21B buyout puts Pharmacyclics execs in line for $4B payoff

Pharmacyclics CEO Robert Duggan would add $3.5 billion to his already substantial wealth, if and when AbbVie's $21 billion buyout goes through. But considering Duggan's record, a multibillion-dollar payoff is to be expected. It's the other executives and directors--who together qualify for more than $575 million--who could inspire M&A envy.

VCA division Antech buys Abaxis vet-lab assets for $21M

Antech Diagnostics, the lab division of veterinary hospital chain VCA, has agreed to buy the assets of Abaxis' Veterinary Reference Laboratory for $21 million in cash.

Trial tech outfit Clinical Ink merges with app upstart

Clinical Ink, a provider of trial data software, is merging with Boston's CentrosHealth in hopes of expanding its platform for paperless studies.

Kite Pharma adds manufacturing assets with T-Cell Factory acquisition

Biotech Kite Pharma, which has become a force in cancer immunotherapy, has added some more manufacturing capabilities to the operations it has been beefing up.

Retrophin bags rare disease approval, FDA voucher in $75M deal

Orphan drug biotech Retrophin is the new owner of an FDA-approved rare disease treatment and a potentially lucrative voucher for a future speedy review thanks to a $75 million buyout agreement.

Endo's shown it's willing to spend. But with Salix gone, what's left worth buying?

As Endo showed last week with its failed $10 billion bid for North Carolina's Salix, it's willing to shell out some serious dough if the right target comes along. The question is, what's left?

CAR-T player Kite Pharma buys its way into Europe and pads its anticancer arsenal

Kite Pharma, a leader among companies in the fast-moving field of cancer immunotherapy, is expanding its arsenal of potential treatments and making European landfall with a biotech buyout.

All clear for Actavis to become Allergan as EU watchdogs approve $66B merger

Actavis and Allergan can finally celebrate: They've cleared the last hurdle to closing their $66 billion merger agreement.

Pfizer chief gets a pay boost, but two underlings get bigger ones

Pfizer CEO Ian Read got a nice pay bump for 2015, with a total package of $23.3 million--more than one-quarter bigger than the previous year's total. But a big chunk of that increase came in the value of his pension. Back that out, and Read's compensation only grew by $280,000.